Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress
Panel participants include:
The scheduled times, titles and locations of the nine speaker presentations are as follows:
- U. Chakravarthy, S. Taylor, C. Bailey, F. Koch, J. Souza UK
ILUVIEN® (190 micrograms fluocinolone acetonide) real-life safety and effectiveness following usage in three European countries – results from the 2016 extract of data from the ILUVIEN® Registry Safety,
Thursday, September 7, 9:18 a.m., Room 117(Level 1).
- A. Augustin GERMANY
Results from the RETRO-IDEAL study assessing the real-world ILUVIEN® (fluocinolone acetonide) outcomes in patients with chronic diabetic macular edema (DME) up to 3 years after therapy was initiated,
Thursday, September 7, 2:30 p.m., Room 117(Level 1).
- C. Currie, S. Holden, D. Owens
Evaluation of the clinical effectiveness in routine practice of the fluocinolone acetonide intravitreal implant in patients with diabetic macular edema,
Thursday, September 7, 2:48 p.m., Room 117(Level 1).
- L. Weber, S. Marx, G. Auffarth, S. Sel, A. Scheuerle, T. Tandogan, R. Khoramnia GERMANY
Fluocinolone acetonide intravitreal implant for treatment of non-infectious uveitic macular edema,
Friday, September 8, 12:06 p.m., Room 111(Level 1).
- C. Pavesio UK
An injectable fluocinolone acetonide intravitreal insert in patients with chronic non-infectious uveitis affecting the posterior segment of the eye: Effects on macular edema at 6 months,
Friday, September 8, 12:18 p.m., Room 111(Level 1).
- J. Coelho, B. Pessoa, A. Abreu, N. Correia, N. Ferreira,
J. Melo Beirao, A. Meireles PORTUGAL
Efficacy and safety of fluocinolone acetonide implant in vitrectomised and non-vitrectomized eyes for treatment of chronic diabetic macular edema,
Saturday, September 9, 3:30 p.m., Room 120(Level 1).
- M. Rehak, M. Tuisl, C. Jochmann, P. Wiedemann GERMANY
Fluocinolone acetonide intravitreal implant for treatment of diabetic macular edema. Long term real life results,
Saturday, September 9, 5:18 p.m., Room 120(Level 1).
- A. Meireles, C. Teixeira, J. Castro e Sousa, M. Falcao, J. Coelho, R. Goncalves, B. Pessoa PORTUGAL
Report of 12 months efficacy and safety of ILUVIEN® (0.2 μg/d fluocinolone acetonide [FAC]) for chronic diabetic macular edema in
Portugal, Sunday, September 10, 8:42 a.m., Room 120(Level 1).
- D. Sahota, H. Ibrahim, R. Sivaraj UK
Identifying patients appropriate for treatment with fluocinolone acetonide (ILUVIEN®). When do we switch from anti-VEGF in diabetic macular edema? A retrospective audit in a
UKsingle-center setting, Sunday, September 10, 11:06 a.m., Room 117(Level 1).
U.S. website www.ILUVIEN.com
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.
ILUVIEN'S E.U. Indication
ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.
For press inquiries:
Katie Brazelfor Alimera Sciences404-317-8361 email@example.com For investor inquiries: CG Capitalfor Alimera Sciences877-889-1972 firstname.lastname@example.org